Asymchem, a CDMO of Intermediates and API's for the pharmaceutical industry, announced yesterday that it has added Dr Scott A May to the Asymchem Board of Scientific Advisors.
Dr May joins Professors Barry Sharpless, Phil Baran, Stephen Buchwald and others currently on the advisory board.
Dr May received his P.D in Chemistry from Indiana University at Bloomington in 1998. In that same year, Dr May joined the Process Research group at Eli Lilly as a senior organic chemist in 1998, and is currently a research fellow in the Small Molecule Design and Development group.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval